On May 13, imine, a brand under CHANDO Group, successfully hosted a themed salon at CBE China Beauty Expo on the “Expert Consensus on Non-Pharmacological Intervention and Management of Pediatric Atopic Dermatitis & Clinical Observation Research Report on imine Intensive Care Cream.”
At the event, imine released three major scientific research achievements. Backed by authoritative medical expertise, robust clinical data, and a complete product system, these achievements further strengthen imine’s positioning as a leading infant and child skincare brand co-created through medical research. They also provide standardized and practical solutions for the scientific care of pediatric atopic dermatitis, highlighting the strong R&D capabilities and broad potential of Chinese functional skincare for infants and children.
As a common chronic inflammatory skin disease among infants and young children, pediatric atopic dermatitis, or AD, causes dryness, itching, redness, and repeated flare-ups, affecting countless families. Non-standardized care is one of the key causes of recurrence.
Targeting the skincare needs of infants and children with problem-prone skin, imine has joined hands with the National Children’s Medical Center and Children’s Hospital of Fudan University to build a full-chain research system integrating medical consensus, clinical validation, and product application. This effort helps drive the industry’s upgrade from basic safety to science-based efficacy.
The three major research achievements released at the salon mark an important milestone for the industry.
The First Authoritative Expert Consensus Fills a Gap in Industry Standards
The Expert Consensus on Non-Pharmacological Intervention and Management of Pediatric Atopic Dermatitiswas officially released. Led by Professor Li Ming from Children’s Hospital of Fudan University, National Children’s Medical Center, and jointly developed by 33 authoritative pediatric dermatology experts, the consensus clearly establishes the core principle of “30% treatment, 70% care.”
It builds an integrated system covering prevention, standardized care, and health guidance, providing an authoritative and practical guide for clinical practice, home care, and the broader industry. The release of the consensus marks a new stage of standardization for non-pharmacological intervention in pediatric AD.
Clinical Data Provides Strong Validation of the Intensive Care Cream’s Efficacy
The clinical observation research report on imine Soothing Intensive Care Cream was also officially unveiled. Clinically validated by Children’s Hospital of Fudan University, continuous use of the Little Green Jar AD Cream for 28 days reduced the recurrence rate of skin problems by three times, addressing the long-standing industry challenge of high recurrence in infant and child eczema.
Powered by the patented ingredient “Fu’er Aibeijian,” the product helps regulate the skin microecological barrier and strengthen the skin’s resilience, thereby reducing the recurrence rate of eczema.
The related research won the 2025 ESDR POST Award from the European Society for Dermatological Research, becoming the only academic achievement from Asia to receive this honor. This recognition reflects strong international endorsement from the dermatology community.
Medical Research Achievements Put into Practice, Positioning imine as a Leader in Functional Infant and Child Skincare
Starting from clinical insights into parenting pain points, and guided by the Expert Consensus, imine has developed a segmented functional care product system focused on prevention, supportive care, and recurrence reduction.The system covers common infant and child skin concerns such as eczema, perioral dermatitis, diaper rash, heat rash, and photodamage. Across the entire product line, more than 90% of ingredients are naturally derived, and the products are suitable for sensitive skin, truly making science a more effective expression of love.
Medical research co-creation is imine’s core competitive strength. The brand has formed an in-depth medical research partnership with the National Children’s Medical Center and Children’s Hospital of Fudan University, jointly establishing a research center. By combining the hospital’s more than 70 years of clinical experience with CHANDO Group’s R&D capabilities, imine has spent six years refining its research and products, completing real-user testing among 1,340 participants and clinical validation on 188 babies.These efforts have led to major research outcomes including the Expert Consensus on Non-Pharmacological Intervention and Management of Pediatric Atopic Dermatitis and the Clinical Observation Research Report on Reducing Eczema Recurrence.With its solid medical research achievements, imine has received market certification as a leading infant and child skincare brand co-created through medical research, becoming a standout player in the functional infant and child skincare sector.
In an era of science-based parenting, imine stays true to its original belief of “loving every child as your own.” With scientific research, the brand helps make parenting more reassuring; with professional efficacy, it addresses real parenting challenges.The release of these three major achievements not only reinforces imine’s leading position in infant and child eczema care and skin microecology, but also helps drive the high-quality development of Chinese infant and child skincare toward medical research co-creation and science-based efficacy.
